Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Korean Med Assoc. 2009 Jul;52(7):657-664. Korean. Original Article. https://doi.org/10.5124/jkma.2009.52.7.657
Ko HJ , Kim HY .
Department of Rheumatology, The Catholic University of Korea College of Medicine, Korea. kohj8804@catholic.ac.kr, ho0919@catholic.ac.kr
Abstract

ARheumatoid arthritis is a systemic, inflammatory, autoimmune disorder of unknown origins. Enhanced understanding of molecular pathogenesis has enabled the development of new biologic treatment that focuses on selective parts of immune system. Combined genetic and environmental factors in association with the risk of rheumatoid arthritis have received increased attention. Research undertaken on the longitudinal disease process and molecular pathology of joint inflammation has contributed to the development of new therapeutic strategies that promote early use of disease-modifying anti-rheumatic drugs (DMARDs) with tight disease control and measurable treatment outcome. Such approach can be beneficial for control of inflammatory activity and joint destruction. We need to find out how to tailor the best individualized treatment in accordance with different cases.

Copyright © 2019. Korean Association of Medical Journal Editors.